{'fraction_non_alphanumeric': 0.017123287671232876, 'fraction_numerical': 0.0, 'mean_word_length': 5.1328671328671325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunotherapy of brain tumors.

The fight against neoplasia still represents a formidable challenge. At the present time the mechanism of cell-mediated immunity seems to offer the most promise. At the same time, one is cautioned by the implication that minimal cell-mediated responses threaten acceleration of tumor growth. Therefore, one is impressed with the need for investigation of these approaches in a model system prior to their application to humans. The data currently available suggest that when active tumor growth is present within the host, a state of immune deficiency exists: cell-mediated immune responses may be quantitatively deficient or this response may be negated by the presence of blocking factor in the serum. Efficient and effective immune responses imply adequate cell-mediated immunity and the absence of blocking factor activity within the serum.